Share on StockTwits

Acceleron Pharma (NASDAQ:XLRN) SVP John D. Quisel sold 13,000 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $29.98, for a total transaction of $389,740.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Acceleron Pharma (NASDAQ:XLRN) traded down 0.50% on Friday, hitting $29.81. 140,234 shares of the company’s stock traded hands. Acceleron Pharma has a 52 week low of $16.78 and a 52 week high of $57.89. The stock’s 50-day moving average is $29.77 and its 200-day moving average is $36.09. The company’s market cap is $947.9 million.

Acceleron Pharma (NASDAQ:XLRN) last announced its earnings results on Tuesday, August 12th. The company reported ($0.54) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.55) by $0.01. On average, analysts predict that Acceleron Pharma will post $-1.44 earnings per share for the current fiscal year.

A number of research firms have recently commented on XLRN. Analysts at Leerink Swann initiated coverage on shares of Acceleron Pharma in a research note on Thursday. They set an “outperform” rating and a $57.00 price target on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Acceleron Pharma in a research note on Wednesday. They set an “outperform” rating and a $47.00 price target on the stock. Four research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $51.00.

Receive News & Ratings for Acceleron Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.